Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Viatris (VTRS)

Viatris adds two directors, Frank D'Amelio and Michael Severino, as two others retire

Neutral Impact 2 of 5 leadership Written later

Viatris appointed Frank D'Amelio, former Pfizer CFO, and Michael Severino, M.D., former AbbVie executive, to its Board of Directors effective May 5, 2025, expanding the Board from 12 to 14 seats. Directors Rajiv Malik and Harry Korman will retire at the end of their current terms in December 2025, following the 2025 Annual Meeting. The filing reports no financial results, and it describes a Board change rather than a financial event.

Key points

  • Board size increased from 12 to 14 directors, effective May 5, 2025
  • Frank D'Amelio joins the Finance Committee; Michael Severino joins the Science and Technology Committee
  • Rajiv Malik and Harry Korman will not stand for re-election at the 2025 Annual Meeting and will retire at the end of their current terms
  • Retirements were not the result of any disagreement with the company on operations, policies, or practices

The filing

CompanyViatris (VTRS)
Form8-K, current report
Filed with the SECMay 5, 2025, 4:45 PM ET
Accession number0001140361-25-017356

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.